This is a working overview of NAD+, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-29 and is reviewed periodically as new material appears.
Natural sources of NMN include mammals, plants, and microorganisms, where it functions as an intermediate in NAD+ salvage and biosynthesis pathways. In mammals, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferase. Some foods contain measurable NMN, but reported amounts vary widely by species, tissue, and analytical method. The extent to which dietary NMN contributes to cellular NAD+ pools remains an open research question.
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. The compound exists in cells as an intermediate in the production of nicotinamide adenine dinucleotide, a central redox cofactor. NMN is distinct from nicotinamide riboside, another related pyridine nucleotide, although the two compounds can converge in metabolic pathways. Its chemical formula is C11H15N2O8P, and it carries a net negative charge at physiological pH.
In the salvage pathway, NMN is generated from nicotinamide and 5-phosphoribosyl-1-pyrophosphate by the enzyme nicotinamide phosphoribosyltransferase. A second route produces NMN from nicotinamide riboside through phosphorylation by nicotinamide riboside kinases. NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases, often called NMNAT enzymes. This stepwise route allows cells to recycle nicotinamide and maintain NAD+ levels under changing metabolic conditions. The relative contribution of each route varies by tissue, species, and physiological state, and it remains an active area of research.
Research on NMN has expanded because NAD+ concentrations decline with age in some tissues and because NAD+ participates in energy metabolism, DNA repair, and signaling. Animal studies have reported changes in NAD+ levels after NMN administration, but human data are more limited and often focus on safety, pharmacokinetics, and biomarker changes. Questions remain about oral absorption, tissue distribution, and whether changes in blood NAD+ reflect changes inside specific organs. NMN is not an approved drug, and claims about its clinical effects should be distinguished from established biochemical findings.
| Property | Value | Notes |
|---|---|---|
| Common name | Nicotinamide mononucleotide | Often abbreviated NMN |
| Chemical formula | C11H15N2O8P | Beta anomer form |
| Molecular mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | Beta-NMN |
| Appearance | White to off-white powder | Typical laboratory grade |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
== General sources == Aniszewski, Tadeusz (2007). Alkaloids: secrets of life. Amsterdam: Elsevier. ISBN 978-0-444-52736-3. Begley, Tadhg P. (2009). Encyclopedia of Chemical Biology. Vol. 10. Wiley. pp. 1569–1570. doi:10.1002/cbic.200900262. ISBN 978-0-471-75477-0. Brossi, Arnold (1989). The Alkaloids: Chemistry and Pharmacology. Academic Press. Dewick, Paul M. (2002). Medicinal Natural Products: A Biosynthetic Approach (Second ed.). Wiley. ISBN 978-0-471-49640-3. Fattorusso, E.; Taglialatela-Scafati, O. (2008). Modern Alkaloids: Structure, Isolation, Synthesis and Biology. Wiley-VCH. ISBN 978-3-527-31521-5. Grinkevich NI; Safronich LN, eds. (1983). The chemical analysis of medicinal plants (in Russian). Moscow: Vysshaya Shkola. Hesse, Manfred (2002). Alkaloids: Nature's Curse or Blessing?. Wiley-VCH. ISBN 978-3-906390-24-6. Knunyants, IL (1988). Chemical Encyclopedia. Soviet Encyclopedia. Orekhov, AP (1955). Chemistry alkaloids (Acad. 2nd ed.). Moscow.{{cite book}}: CS1 maint: location missing publisher (link) Plemenkov, VV (2001). Introduction to the Chemistry of Natural Compounds. Kazan.{{cite book}}: CS1 maint: location missing publisher (link) Saxton, J. E. (1971). The Alkaloids: A Specialist Periodical Report. London: The Chemical Society. Veselovskaya, N. B.; Kovalenko, A. E. (2000). Drugs. Moscow: Triada-X. Wink, M (2009). "Mode of action and toxicology of plant toxins and poisonous plants". Mitt. Julius Kühn-Inst. 421: 93–112x.
==== Thymomas ==== Tumours originating from the thymic epithelial cells are called thymomas. They most often occur in adults older than 40. Tumours are generally detected when they cause symptoms, such as a neck mass or affecting nearby structures such as the superior vena cava; detected because of screening in patients with myasthenia gravis, which has a strong association with thymomas and hyperplasia; and detected as an incidental finding on imaging such as chest X-rays. Hyperplasia and tumours originating from the thymus are associated with other autoimmune diseases – such as hypogammaglobulinemia, Graves disease, pure red cell aplasia, pernicious anaemia and dermatomyositis, likely because of defects in negative selection in proliferating T cells. Thymomas can be benign; benign but by virtue of expansion, invading beyond the capsule of the thymus ("invasive thymoma"), or malignant (a carcinoma). This classification is based on the appearance of the cells. A WHO classification also exists but is not used as part of standard clinical practice. Benign tumours confined to the thymus are most common, followed by locally invasive tumours, and then by carcinomas. There is variation in reporting, with some sources reporting malignant tumours as more common. Invasive tumours, although not technically malignant, can still spread (metastasise) to other areas of the body. Even though thymomas originate from epithelial cells, they can also contain thymocytes. Treatment of thymomas often requires surgery to remove the entire thymus.
== Limitations == Limitations of magnetic drug delivery can range from their inherent magnetic properties to interactions with bodily barriers. When magnetic nanoparticles are in the bloodstream, they have high solubility and ionic strength, allowing them to interact with plasma proteins, stimulating the immune system to further inhibit their function. Additionally, the proportion of the nanoparticle size to the target tissue has shown limitations in effective drug delivery, especially in the kidneys and the brain. Intracellular barriers include the removal of the magnetic nanoparticles from the target membrane by ligand-dependent endocytosis followed by separation via acidification in the endosome chamber. Other barriers to consider are the depth of the target tissue, vascular sources, body weight, the speed and amount of blood flow to the target tissue, distance from the field source, injection route, and tumor volume. However, the use of magnetic nanoparticles is more effective when used in near-surface tissues that have slower blood flow, allowing for diffusion and/or endocytosis of nanoparticles into the tissue. Another limitation involves the accumulation of nanoparticles only 5 mm away from an external magnet. An accumulation distance of 5 mm may not be sufficient in larger applications of magnetic drug delivery. This may be effective enough for sites in closer proximity to the surface of the body, but when the site of interest is deeper within tissue, then the advantage of using magnetic nanoparticles for delivery decreases exponentially.
Sources: en.wikipedia.org
== Book chapters == 1. Richoz O, Hafezi F Modifications for Thin Corneas, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 51–55. 2. Hafezi F, Mavrakanas N Corneal Collagen Cross-Linking for Postoperative Corneal Ectasia, in Corneal collagen cross-linking, Randleman B, Hafezi F, Editors. 2013, Slack Inc.: Thorofare, NJ, USA. 75–81. 3. Pajic B, Latinovic S, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Fankhauser F Lamellar corneal resection with LDV Crystal line femtosecond laser after penetrating keratoplasty, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 4. Pajic B, Hafezi F, Pajic-Eggspuehler B, Mrochen M, Mueller J, Pajic D, Fankhauser F Applanation-free femtosecond laser processing of the cornea, in Femtosecond laser technology, Gark A, Editor. 2012, Jaypee Brothers: Mumbai. 5. Iseli HP, Hafezi F, Mrochen M, Seiler T Estado actual de la reticulación del colágeno corneal, in Técnicas de modelado corneal: desde la ortoqueratologia hasta el cross-linking, Cezón Prieto J, Editor. 2009, Sociedad Española de Cirurgia Ocular Implanto-Refractiva: Madrid. 381–86. 6. Hafezi F, Iseli HP, Seiler T Automated anterior lamellar keratoplasty for the management of complications in refractive surgery, in Surgical techniques in anterior and posterior lamellar corneal surgery, John T, Editor. 2005, Slack Inc.: New York. (in press). 7.
==== Chalcogenides and pnictides ==== Indium derivatives of chalcogenides (O, S, Se, Te) are well developed. Indium(III) oxide, In2O3, forms when indium metal is burned in air or when the hydroxide or nitrate is heated. The analogous sesqui-chalcogenides with sulfur, selenium, and tellurium are also known. The chemistry of indium pnictides (N, P, As, Sb) is also well known, motivated by their relevance to semiconductor technology. For applications in microelectronics, the P, As, and Sb derivatives are made by reactions of trimethylindium:
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine. It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. It was developed under the name ARCT-154, also known as VBC-COV19-154 in Vietnam, by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing. Zapomeran was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved. Zapomeran was authorized for medical use in the European Union in February 2025, and in the UK in January 2026.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in NAD+ biosynthesis.
No. NMN is a precursor that can be converted to NAD+ in cells. NAD+ is the larger dinucleotide that participates in many redox reactions.
Small amounts of NMN have been reported in several foods, including certain vegetables and fruits. The measured levels vary, and the significance of dietary intake is not fully established.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide and an intermediate in the cellular production of NAD+.